Related Experiment Videos
Low-dose isotretinoin in severe acne
M Bellosta1, M Vignini, L Miori
1Clinica Dermatologica, University of Pavia, Italy.
International Journal of Tissue Reactions
|January 1, 1987
Summary
Low-dose isotretinoin effectively treats severe acne, including pustular, nodular, and cystic types, in patients resistant to antibiotics. Treatment is generally safe, with minimal side effects reported, supporting its use in specific cases.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Severe acne, including pustular, nodular, and cystic forms, often proves resistant to conventional systemic antibiotic therapies.
- Alternative treatment options are crucial for patients with refractory acne vulgaris.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose isotretinoin in patients with severe acne unresponsive to antibiotics.
- To determine the optimal dosage and treatment duration for this patient group.
Main Methods:
- A cohort of 60 patients with antibiotic-resistant severe acne was treated with low-dose isotretinoin (0.5 mg/kg/day).
- Treatment duration ranged from 12 to 20 weeks.
- Serum lipid profiles were monitored for potential adverse effects.
Main Results:
- Low-dose isotretinoin demonstrated significant efficacy across pustular, nodular, and cystic acne lesions.
- Treatment was well-tolerated, with only one patient discontinuing due to elevated serum cholesterol and triglycerides.
- The therapeutic benefit was observed even with the reduced dosage regimen.
Conclusions:
- Low-dose isotretinoin is an effective therapeutic option for severe, antibiotic-resistant acne vulgaris.
- Careful monitoring of lipid levels is advised during treatment.
- The authors recommend restricting this treatment to severe acne cases under medical supervision.